PR01.06 Integrating Circulating Genetically Abnormal Cells to Early Lung Cancer Screening in Chinese Bus Drivers

Chen, B.; Huang, Yujuan; Yang, Xi; Huang, Chi-Hsien; Ye, X.; Tang, Daiwei; Zhang, J.; Bai, Chunxue

doi:10.1016/j.jtho.2020.10.083

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An environmental study that employed the 4-color FISH assay showed an 89.47% sensitivity and an 85.00% specificity to detect LC in 89 Chinese bus drivers who had indeterminate lung nodules on LDCT following chronic and consistent exposure to occupational pollutants [92]. Similarly, Liu et al in a prospective The workflow of CAC enumeration, from left to right, collection of 10 ml of peripheral blood, enrichment of peripheral blood mononuclear cells, hybridization of FISH probes, fluorescence image acquisition and analysis followed by cloud based data review and report [90].…”

Section: Fluorescence-in-situ Hybridization or Fish-based Assaysmentioning

confidence: 99%

Diagnosis of Non-Small Cell Lung Cancer via Liquid Biopsy Highlighting a Fluorescence-in-situ-Hybridization Circulating Tumor Cell Approach

Ye¹,

Xiao²,

Carbone³

et al. 2021

Pathology - From Classics to Innovations

View full text Add to dashboard Cite

Lung cancer (LC), is the most common and lethal cancer worldwide. It affects both sexes and in its early stages is clinically silent, until it reaches a more advanced stage, when it becomes highly incurable. In order to improve the high mortality associated with LC there has been an urgent need for screening high risk patients by low dose CT scan (LDCT) for the early detection of small resectable malignant tumors. However, while highly sensitive to detect small lung nodules, LDCT is non-specific, resulting in a compelling need for a complementary diagnostic tool. For example, a non-invasive blood test or liquid biopsy, (LB), could prove quite useful to confirm a diagnosis of malignancy prior to definitive therapy. With the advent of LB becoming increasingly clinically accepted in the diagnosis and management of LC, there has been an explosion of publications highlighting new technologies for the isolation of and detection of circulating tumor cells (CTCs) and cell free tumor DNA (cfDNA). The enormous potential for LB to play an important role in the diagnosis and management of LC to obtain valuable diagnostic information via an approach that may yield equivalent information to a surgical biopsy, regarding the presence of cancer and its molecular landscape is described.

show abstract

Section: Fluorescence-in-situ Hybridization or Fish-based Assaysmentioning

confidence: 99%